Redeye gives an additional comment on yesterday’s interim data in Vicore’s phase II IPF study. While early and indicative, we find the results very encouraging and potentially game-changing if replicated in the final study (and subsequent phase IIb and III studies). We slightly increase our already aggressive LoA and raise our base case to SEK 64 (62).
